Ongoing Projects
2021-2025
Mentoring Patient-Oriented Pharmacoepidemiologic Research in Rheumatic Diseases
NIH-NIAMS/ K24AR078959
This 5-year project aims to evaluate comparative effectiveness and safety of biologic and ts-DMARDs in patients with RA using real-world data, to identify important predictors of safety events associated with use of biologic or ts-DMARDs, and to conduct a patient-centered benefit-risk assessment of these drugs incorporating patients’ preferences.
2019 - 2022
Comparative Effectiveness of Treat-To-Target Approach versus Routine Care in Management of Gout
NIH – NIAMS R01AR073314
This 3-year research proposal examines the comparative effectiveness of the two different treatment strategies, Treat-To-Target versus usual care, for management of chronic gout in a real-world setting.
Mentoring Patient-Oriented Pharmacoepidemiologic Research in Rheumatic Diseases
NIH-NIAMS/ K24AR078959
This 5-year project aims to evaluate comparative effectiveness and safety of biologic and ts-DMARDs in patients with RA using real-world data, to identify important predictors of safety events associated with use of biologic or ts-DMARDs, and to conduct a patient-centered benefit-risk assessment of these drugs incorporating patients’ preferences.
2019 - 2022
Comparative Effectiveness of Treat-To-Target Approach versus Routine Care in Management of Gout
NIH – NIAMS R01AR073314
This 3-year research proposal examines the comparative effectiveness of the two different treatment strategies, Treat-To-Target versus usual care, for management of chronic gout in a real-world setting.
Past Projects
2018-2021
Risk of Incident Diabetes or Worsening Diabetes in Patients with Rheumatoid Arthritis
Bristol-Myers Squibb
We examined the risk of diabetes in patients with rheumatoid arthritis and impact of different types of disease-modifying antirheumatic drugs on the risk of diabetes.
2018-2020
Comorbidities and other clinical factors related to systemic treatment use in patients with psoriatic arthritis
Pfizer
This study aimed to provide a claims-based algorithm to identify patients with psoriatic arthritis (PsA) with and without psoriasis and to assess comorbidities and other clinical factors associated with systemic treatment for PsA in a real-world setting.
2018-2020
Identification and outcomes of interstitial lung disease in patients with rheumatoid arthritis using the linked Medicare-EMR database
Bristol-Myers Squibb
We developed a claims-based algorithm to identify interstitial lung disease (ILD) in RA patients and conduct a study to characterize treatment patterns in RA patients with ILD.
2016-2020
Use and safety of opioids in patients undergoing total joint replacement
NIH-NIAMS R01 AR 069557
This project examines how patients with osteoarthritis use opioids before and after total joint replacement and to assess the effect of opioid use on clinical outcomes and safety events after joint replacement, using data from Medicare linked with the Function and Outcomes Research for Comparative Effectiveness in Total Joint Replacement (FORCE-TJR) registry.
2018-2019
ICD9 to ICD10 Mapping for BBCIC conditions of interest
Biologics & Biosimilars Collective Intelligence Consortium
This study examines the performance of different ICD-9 to ICD-10 mapping approaches for the selected disease areas related to clinical indications of biosimilars (i.e., end-stage renal disease/dialysis, neutropenia due to various causes, and systemic inflammatory diseases).
2016-2018
Comparative safety of tocilizumab versus other biologic DMARDs in patients with rheumatoid arthritis
Roche
The main objective of this research proposal is to compare rates of different safety events including malignancy excluding non-melanoma skin cancer, serious bacterial or viral infection, opportunistic infection and herpes zoster.
2017-2018
Recommended approaches to BBCIC conduct of observational switching studies
Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)
The purpose of this Workgroup will be to improve the conduct of biosimilar switching studies by reviewing the literature to identify potential challenges related to suitable data sources and methods for biosimilar switching studies, and establishing recommendations for best practices in the conduct of innovator and biosimilar switching studies and recommendations for the treatment of switching/sequencing as a covariate/confounder in a comparative effectiveness study of anti-inflammatory biologics.
2016-2018
Comparative safety of biologic DMARDs in RA patients with cardiovascular, metabolic and pulmonary comorbidities: A large population-based cohort study
Bristol-Myers Squibb
This is a large cohort study using Medicaid and other large-scale population-based health care utilization data to examine the comparative safety of various biologic DMARDs in RA patients.
2016-2018
Xanthine oxidase inhibitors and risks of myocardial infarction and diabetes
NIH-NIAMS R21-AR069271
The aims of this study are to examine the effect of xanthine oxidase inhibitor (XOI) on the risk of incident myocardial infarction (MI) in patients with gout, to investigate the effect of XOI on the risk of incident type 2 diabetes in patients with gout, and to estimate the effect of XOI on myocardial infarction and type 2 diabetes, adjusted for treatment adherence, in patients with gout.
2015-2017
Secular Trends and Sequential Patterns of DMARD use and Adherence to DMARDs in Rheumatoid Arthritis
Pfizer
This study is to provide detailed and high-quality evidence on time trends and sequential patterns of disease-modifying antirheumatic drug (DMARD) use in patients with rheumatoid arthritis (RA) and to evaluate patients’ adherence to DMARD and associated factors.
2016-2017
Evaluating the role of healthcare system characteristics-based instrumental variables for confounding control in observational studies
Merck
This project aims to improve the predictive capacity of observational studies by implementing advanced statistical methodology using instrumental variables.
2015-2016
Risk of cardiovascular events in patients using tocilizumab as compared with other biologics using data from multiple large healthcare claims databases
Genentech
This is a cohort study to quantify or refute any residual cardiovascular risk that the use of tocilizumab may cause in patients with RA using observational methods in large healthcare databases.
2010-2015
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis
National Institutes of Health (NIH)-NIAMS K23 AR059677
The major goal of this study was to examine risk of human papillomavirus (HPV) infection, cervical dysplasia and cervical cancer in patients with rheumatoid arthritis (RA).
2011-2014
Medication adherence and characteristics of health care utilization in patients treated with amitriptyline, pregabalin, duloxetine or gabapentin for fibromyalgia
Pfizer
The goal of this study was to examine health care resource use and medication adherence over time in patients newly starting amitriptyline, pregabalin, duloxetine or gabapentin for fibromyalgia.
Risk of Incident Diabetes or Worsening Diabetes in Patients with Rheumatoid Arthritis
Bristol-Myers Squibb
We examined the risk of diabetes in patients with rheumatoid arthritis and impact of different types of disease-modifying antirheumatic drugs on the risk of diabetes.
2018-2020
Comorbidities and other clinical factors related to systemic treatment use in patients with psoriatic arthritis
Pfizer
This study aimed to provide a claims-based algorithm to identify patients with psoriatic arthritis (PsA) with and without psoriasis and to assess comorbidities and other clinical factors associated with systemic treatment for PsA in a real-world setting.
2018-2020
Identification and outcomes of interstitial lung disease in patients with rheumatoid arthritis using the linked Medicare-EMR database
Bristol-Myers Squibb
We developed a claims-based algorithm to identify interstitial lung disease (ILD) in RA patients and conduct a study to characterize treatment patterns in RA patients with ILD.
2016-2020
Use and safety of opioids in patients undergoing total joint replacement
NIH-NIAMS R01 AR 069557
This project examines how patients with osteoarthritis use opioids before and after total joint replacement and to assess the effect of opioid use on clinical outcomes and safety events after joint replacement, using data from Medicare linked with the Function and Outcomes Research for Comparative Effectiveness in Total Joint Replacement (FORCE-TJR) registry.
2018-2019
ICD9 to ICD10 Mapping for BBCIC conditions of interest
Biologics & Biosimilars Collective Intelligence Consortium
This study examines the performance of different ICD-9 to ICD-10 mapping approaches for the selected disease areas related to clinical indications of biosimilars (i.e., end-stage renal disease/dialysis, neutropenia due to various causes, and systemic inflammatory diseases).
2016-2018
Comparative safety of tocilizumab versus other biologic DMARDs in patients with rheumatoid arthritis
Roche
The main objective of this research proposal is to compare rates of different safety events including malignancy excluding non-melanoma skin cancer, serious bacterial or viral infection, opportunistic infection and herpes zoster.
2017-2018
Recommended approaches to BBCIC conduct of observational switching studies
Biologics & Biosimilars Collective Intelligence Consortium (BBCIC)
The purpose of this Workgroup will be to improve the conduct of biosimilar switching studies by reviewing the literature to identify potential challenges related to suitable data sources and methods for biosimilar switching studies, and establishing recommendations for best practices in the conduct of innovator and biosimilar switching studies and recommendations for the treatment of switching/sequencing as a covariate/confounder in a comparative effectiveness study of anti-inflammatory biologics.
2016-2018
Comparative safety of biologic DMARDs in RA patients with cardiovascular, metabolic and pulmonary comorbidities: A large population-based cohort study
Bristol-Myers Squibb
This is a large cohort study using Medicaid and other large-scale population-based health care utilization data to examine the comparative safety of various biologic DMARDs in RA patients.
2016-2018
Xanthine oxidase inhibitors and risks of myocardial infarction and diabetes
NIH-NIAMS R21-AR069271
The aims of this study are to examine the effect of xanthine oxidase inhibitor (XOI) on the risk of incident myocardial infarction (MI) in patients with gout, to investigate the effect of XOI on the risk of incident type 2 diabetes in patients with gout, and to estimate the effect of XOI on myocardial infarction and type 2 diabetes, adjusted for treatment adherence, in patients with gout.
2015-2017
Secular Trends and Sequential Patterns of DMARD use and Adherence to DMARDs in Rheumatoid Arthritis
Pfizer
This study is to provide detailed and high-quality evidence on time trends and sequential patterns of disease-modifying antirheumatic drug (DMARD) use in patients with rheumatoid arthritis (RA) and to evaluate patients’ adherence to DMARD and associated factors.
2016-2017
Evaluating the role of healthcare system characteristics-based instrumental variables for confounding control in observational studies
Merck
This project aims to improve the predictive capacity of observational studies by implementing advanced statistical methodology using instrumental variables.
2015-2016
Risk of cardiovascular events in patients using tocilizumab as compared with other biologics using data from multiple large healthcare claims databases
Genentech
This is a cohort study to quantify or refute any residual cardiovascular risk that the use of tocilizumab may cause in patients with RA using observational methods in large healthcare databases.
2010-2015
Cervical Dysplasia and Human Papillomavirus Infection in Rheumatoid Arthritis
National Institutes of Health (NIH)-NIAMS K23 AR059677
The major goal of this study was to examine risk of human papillomavirus (HPV) infection, cervical dysplasia and cervical cancer in patients with rheumatoid arthritis (RA).
2011-2014
Medication adherence and characteristics of health care utilization in patients treated with amitriptyline, pregabalin, duloxetine or gabapentin for fibromyalgia
Pfizer
The goal of this study was to examine health care resource use and medication adherence over time in patients newly starting amitriptyline, pregabalin, duloxetine or gabapentin for fibromyalgia.
|
PRIME is a program of Division of Phamacoepidemiology & Pharmacoeconomics
|
|
Proudly powered by Weebly